Novo Nordisk Threatens Legal Action Over $200/Month Compounded Wegovy Alternative
Novo Nordisk has threatened legal action against Hims & Hers over its compounded semaglutide formulation marketed as a lower-cost Wegovy alternative. The telehealth company plans to sell compounded doses at about $200 per month, undercutting Wegovy’s list price above $1,300, potentially eroding Novo Nordisk’s U.S. weight-loss sales.
1. Hims & Hers Introduces Compounded Semaglutide
Hims & Hers has launched a compounded version of semaglutide designed to mimic Wegovy’s weight-loss effects, partnering with a compounding pharmacy network to deliver monthly doses for about $200. The telehealth provider targets cost-conscious patients by offering 2.4 mg doses and home delivery, positioning its product as a cheaper alternative to Wegovy’s list price above $1,300.
2. Novo Nordisk’s Legal Response
Novo Nordisk has warned that the compounded formulation infringes its patents covering semaglutide’s use for obesity management and advanced delivery methods. The company is evaluating cease-and-desist notices and potential litigation to protect its intellectual property, aiming to safeguard Wegovy’s market exclusivity and revenue in the U.S. weight-management segment.